INKT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 09:48):

Stats
Today's Volume	2 929.00
Average Volume	97 717.00
Market Cap	31.23M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.380
ATR14	$0.00700 (0.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Behner Peter	Buy	16 185	Common Stock
2024-03-01	Ryan Barbara	Buy	18 685	Common Stock
2024-03-01	Wiinberg Ulf	Buy	15 790	Common Stock
2024-03-01	Corvese Brian	Buy	18 816	Common Stock
2024-01-16	Van Dijk Marcus Antonius	Buy	171 078	Stock Option

INSIDER POWER
-43.75
Last 97 transactions
Buy: 6 422 397 \| Sell: 29 448 104

Volume Correlation

Long: 0.10 (neutral)

Short: -0.29 (neutral)

Signal:(66.519) Neutral

MiNK Therapeutics, Inc. Correlation

10 Most Positive Correlations
MMAC	0.859
EPSN	0.847
CLFD	0.834
NETE	0.828
LYRA	0.825
INPX	0.812
DSGN	0.808
NBIX	0.808
AMRB	0.804
REYN	0.802

10 Most Negative Correlations
RMRM	-0.834
CPAA	-0.829
TIOAU	-0.826
SVAC	-0.818
MTSL	-0.817
CVCO	-0.814
THCP	-0.813
AEAE	-0.813
PAIC	-0.813
TIOA	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MiNK Therapeutics, Inc. Correlation - Currency/Commodity

-0.31
( neutral )

-0.22
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.00
( neutral )

0.34
( neutral )

MiNK Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-204 617 (0.00 %)
EPS:	$-0.650

FY	2023
Revenue:	$0
Gross Profit:	$-204 617 (0.00 %)
EPS:	$-0.650

FY	2022
Revenue:	$2.70B
Gross Profit:	$-28.24B (-1 044.26 %)
EPS:	$-0.740

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.160

Financial Reports:

No articles found.

MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.